OS2.5 Long term remission/survival over 8 years in patients with newly diagnosed glioblastoma (GBM) treated with ICT-107 dendritic cell-based immunotherapy (phase I) | Zendy

AI Assistant Blog Pricing

OS2.5 Long term remission/survival over 8 years in patients with newly diagnosed glioblastoma (GBM) treated with ICT-107 dendritic cell-based immunotherapy (phase I)

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.